Analytical Data
-
Gene name
IGF-I/IGF-1
- Application
-
Alternative Names
Insulin-like growth factor I; IGF-I; MGF; Somatomedin-C; IBP1
-
Species
Mouse
-
Source
P. pastoris
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05017-1
-
Expression Region
G49-A118
-
Protein Length
Full Length of Isoform-1 Mature Protein
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulin-like Growth Factor I (IGF-I), also known as IGF-1, is a crucial peptide hormone that plays a significant role in growth, development, and metabolic regulation. It is primarily produced in the liver in response to growth hormone (GH) stimulation and is involved in cellular growth, differentiation, and survival. Research into IGF-I/IGF-1 recombinant proteins has garnered attention due to their potential therapeutic applications, particularly in conditions characterized by growth deficiencies, such as growth hormone insensitivity, Turner syndrome, and idiopathic short stature. Additionally, IGF-I has been implicated in various metabolic disorders, including obesity and diabetes. The ability to produce recombinant IGF-1 in a laboratory setting allows for the exploration of its biological effects, mechanisms of action, and potential uses in regenerative medicine and muscle-wasting diseases. Furthermore, ongoing studies investigate the role of IGF-I in aging and how it affects tissue repair and muscle regeneration. Despite its therapeutic promise, concerns exist regarding the appropriate usage and potential side effects of IGF-I therapies. As research continues to unveil the complexities of IGF-I signaling pathways and their interactions with other hormonal systems, the development of IGF-I recombinant proteins presents a valuable opportunity to create targeted treatments that can enhance growth and overall metabolic health.
